You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

~ Buy the AIRDUO DIGIHALER (fluticasone propionate; salmeterol xinafoate) Drug Profile, 2024 PDF Report in the Report Store ~

AIRDUO DIGIHALER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Airduo Digihaler, and when can generic versions of Airduo Digihaler launch?

Airduo Digihaler is a drug marketed by Teva Pharm and is included in one NDA. There are twenty-eight patents protecting this drug.

This drug has four hundred and eighty-seven patent family members in thirty-seven countries.

The generic ingredient in AIRDUO DIGIHALER is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for AIRDUO DIGIHALER?
  • What are the global sales for AIRDUO DIGIHALER?
  • What is Average Wholesale Price for AIRDUO DIGIHALER?
Summary for AIRDUO DIGIHALER
Drug patent expirations by year for AIRDUO DIGIHALER
Drug Prices for AIRDUO DIGIHALER

See drug prices for AIRDUO DIGIHALER

US Patents and Regulatory Information for AIRDUO DIGIHALER

AIRDUO DIGIHALER is protected by twenty-eight US patents and two FDA Regulatory Exclusivities.

Patents protecting AIRDUO DIGIHALER

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compliance monitoring module for a breath-actuated inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhalation apparatus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compliance monitoring module for a breath-actuated inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Drug delivery device with electronics and power management
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Inhalation device with integrated electronics
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Drug delivery device with electronics
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Drug delivery device with electronics
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Drug delivery device with electronics
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Drug delivery device with electronics
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhalation apparatus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhalation apparatus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Process for preparing a medicament
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counter for inhaler having a bore and shaft arrangement
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compliance monitoring module for a breath-actuated inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compliance monitoring module for a breath-actuated inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Process for preparing a medicament
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting AIRDUO DIGIHALER

REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST
Exclusivity Expiration: ⤷  Sign Up

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-006 Jul 12, 2019 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-005 Jul 12, 2019 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-005 Jul 12, 2019 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for AIRDUO DIGIHALER

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-005 Jul 12, 2019 ⤷  Sign Up ⤷  Sign Up
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-005 Jul 12, 2019 ⤷  Sign Up ⤷  Sign Up
Teva Pharm AIRDUO DIGIHALER fluticasone propionate; salmeterol xinafoate POWDER;INHALATION 208799-006 Jul 12, 2019 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for AIRDUO DIGIHALER

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Teva B.V. Airexar Spiromax salmeterol xinafoate, fluticasone propionate EMEA/H/C/004267
Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1
Withdrawn no no no 2016-08-18
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for AIRDUO DIGIHALER

See the table below for patents covering AIRDUO DIGIHALER around the world.

Country Patent Number Title Estimated Expiration
Japan 2021183164 呼吸作動式の吸入器用のコンプライアンス監視モジュール (COMPLIANCE MONITORING MODULE FOR BREATH-ACTUATED INHALER) ⤷  Sign Up
Israel 223117 מוני מינון למשאפים ומשאפים ועמודים למשאפים (Dose counters for inhalers and inhalers and shafts thereof) ⤷  Sign Up
Spain 2222525 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for AIRDUO DIGIHALER

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2506844 18C1022 France ⤷  Sign Up PRODUCT NAME: COMBINAISON COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (EN PARTICULIER LE BROMURE D'UMECLIDINIUM), DU VILANTEROL OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (EN PARTICULIER LE TRIFENATATE DE VILANTEROL), ET DU FUROATE DE FLUTICASONE; REGISTRATION NO/DATE: EU/1/17/1236 20171117
2506844 132018000000341 Italy ⤷  Sign Up PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
2506844 2018C/022 Belgium ⤷  Sign Up PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.